Overview

Letrozole Plus Metronomic Capecitabine as First-line Treatment for Patients With Recurrent or Metastatic Breast Cancer

Status:
Not yet recruiting

Trial end date:
2025-05-31

Target enrollment:

Participant gender:

Summary

The study is designed to assess the treatment outcomes following treatment with letrozole plus metronomic capecitabine in patients with hormone receptor-positive, Her2-negative advanced breast cancer who have not received prior systemic anti-cancer therapies for their recurrent /metastatic disease.

Phase:

Phase 2

Details

Lead Sponsor:

Assiut University

Treatments:

Capecitabine
Letrozole